MedTrace Logo

Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment

NCT06372886 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2024-04-18

No results posted yet for this study

Summary

1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT).
2. There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group.
3. PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group.
4. We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.

Conditions

  • Pancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment

Interventions

PROCEDURE

portal/superior vein resection

portal/superior vein resection

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2022-01-01
Completion
2024-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06372886 on ClinicalTrials.gov